ArticleCells2013
Functional assessment of pharmacological telomerase activators in human T cells.
Article in Cells, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Trial
- Review
- The drug discovery and therapeutic nano-strategies targeting cellular senescence.Materials today. Bio · 2025Review
- Article
- Metabolic profiling and biological activity of twoRSC advances · 2023Article
- The telomerase activator TA-65 protects from cigarette smoke-induced small airway remodeling in mice through extra-telomeric effects.Scientific reports · 2023Article
- Telomerase reverse transcriptase and neurodegenerative diseases.Frontiers in immunology · 2023Review
- Efficient production of the anti-aging drug Cycloastragenol: insight from two Glycosidases by enzyme mining.Applied microbiology and biotechnology · 2020Article
- Noncoding telomeric repeat-containing RNA inhibits the progression of hepatocellular carcinoma by regulating telomerase-mediated telomere length.Cancer science · 2020Article
- Telomeres and COVID-19.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- The Use of Natural Agents to Counteract Telomere Shortening: Effects of a Multi-Component Extract ofBiomedicines · 2020Article
- Telomeres as Therapeutic Targets in Heart Disease.JACC. Basic to translational science · 2019Review
- Discovery of potent telomerase activators: Unfolding new therapeutic and anti-aging perspectives.Molecular medicine reports · 2019Article
- Preventive effect of Shenkang injection against high glucose-induced senescence of renal tubular cells.Frontiers of medicine · 2019Article
- Cycloastragenol: An exciting novel candidate for age-associated diseases.Experimental and therapeutic medicine · 2018Review
- Articular Cartilage Aging-Potential Regenerative Capacities of Cell Manipulation and Stem Cell Therapy.International journal of molecular sciences · 2018Review
- Anti-Aging Implications ofAging and disease · 2017Review
- Review
- Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Telomeres are structures at the ends of chromosomes that shorten during cell division and eventually signal an irreversible state of growth arrest known as cellular senescence. To delay this cellular aging, human T cells, which are critical in the immune control over infections and cancer, activate the enzyme telomerase, which binds and extends the telomeres. Several different extracts from the Astragalus membranaceus root have been documented to activate telomerase activity in human T cells. The objective of this research was to compare two extracts from Astragalus membranaceus, TA-65 and HTA, for their effects on both telomerase and proliferative activity of human CD4 and CD8 T cells. Our results demonstrate that, TA-65 increased telomerase activity significantly (1.3 to 3.3-fold relative to controls) in T cell cultures from six donors tested, whereas HTA only increased telomerase levels in two out of six donors. We also demonstrate that TA-65 activates telomerase by a MAPK- specific pathway. Finally, we determine that during a three-day culture period, only the T cells treated with the TA-65 extract showed a statistically significant increase in proliferative activity. Our results underscore the importance of comparing multiple telomerase activators within the same experiment, and of including functional assays in addition to measuring telomerase activity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.